Loading clinical trials...
Loading clinical trials...
A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma
Conditions
Interventions
Betalutin with lilotomab dose 1
Betalutin with lilotomab dose 2
Locations
1
Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Start Date
December 19, 2017
Primary Completion Date
September 1, 2019
Completion Date
September 1, 2020
Last Updated
January 10, 2019
NCT06189391
NCT05006716
NCT06026319
NCT05950165
NCT06876662
NCT05755087
Lead Sponsor
Nordic Nanovector
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions